Tocilizumab and COVID-19: Timing of Administration and Efficacy

Elevated concentrations of interleukin-6 have been demonstrated to be an important key factor in COVID-19 host immune impairment. It represents an important prognostic factor of harm associated with COVID-19 infection by stimulating a vigorous proinflammatory response, leading to the so-called “cyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Abidi, Emna, El Nekidy, Wasim S., Alefishat, Eman, Rahman, Nadeem, Petroianu, Georg A., El-Lababidi, Rania, Mallat, Jihad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894855/
https://www.ncbi.nlm.nih.gov/pubmed/35250575
http://dx.doi.org/10.3389/fphar.2022.825749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894855/
https://www.ncbi.nlm.nih.gov/pubmed/35250575
http://dx.doi.org/10.3389/fphar.2022.825749

Ejemplares similares